-
According to the article, the cost is more and you may not feel the customary “puff” as much with the new devices. The new devices tend to clog easier. The reason for the change, the ozone and chlorofluorocarbon that damage, so even the asthma inhalers are going green, not literally I think...
-
This is the second approval this week for a generic version of Wellbutrin, earlier this week Watson Pharmaceuticals announced it’s new version. BD The Food and Drug Administration approved a generic copy of an antidepressant made by Impax Laboratories Inc. Regulators gave the drug — a copy of GlaxoSmithKline...
-
The entire focus is to see whether or not patent laws have been violated and if less expensive generics were in any way stalled from getting to the market place. It all boils down to intellectual-property rights and patient disputes. Interesting that Teva is settling lawsuits and will be...
-
Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
-
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-25-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
-
Here’s the ribbon breaking ceremony picture. Let’s all hope this is a success and hopefully some new technology will enter the picture as well with remote batch monitoring of products manufactured in China and other locations in the world. There is only so much an in person visit can cover...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-19-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Pharma, FDA, China, Outsourcing, Tainted Food, food contamination, food safety, busines intelligence software, server banks, import/exports, FDA inspections
-
This indeed makes it much more difficult to pin down and see which physicians are using which drugs, but from their own internal sales information each drug company will have sales from drug stores, so the overall business from a pre set territory can be derived, so perhaps a new curve in Pharma marketing...
-
This court case has been in the news of late and now with the current ruling, it adds on one more layer of responsibility to the Name Brand drug company, in other words when the generic versions come out and are prescribed, they can piggyback the exact same warnings, thus the name brand company is now...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-18-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Pharma, Heatlhcare, Side Effects, Warnings, Lawsuits, liability, Generice drugs, drugs. name band drugs
-
This was somewhat of a first for the US FDA to trust Chinese data. Shenzhen Chipscreen Bio sciences Ltd. was also awarded the Most Valued Partner for Roche R&D Center. Oncology drugs are one of their primary focuses, with individuals trained here in the US and returning to China to create their...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-15-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, FDA, Oncology, R and D, China pharma, Chipscreen, biosciences, HUYA
-
I don’t think in view of the current events, there was a lot of choice here for the FDA, and we do need to know that the quality of both our food and pharmaceutical products is good. One thing in particular that springs to mind for me here here is perhaps some use of business intelligence for monitoring...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-13-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, Pharma, FDA, Tainted Food, food contamination, food safety, busines intelligence software, server banks, import/exports, FDA inspections
-
At first you may say this is old stuff, but the new version does much more than just take pictures on it’s way through your system, this one disperses medication, and that’s the whole idea is to have a pill put the medicine on target, where it needs to be with digestive problems such as treating Crohn...
-
A brief summary of what is in the news this week. BD Glaxo to shutter 620-worker U.K. plant The latest casualty of impending drug-patent expirations is a GlaxoSmithKline plant in Kent, England. The drugmaker says it will shutter the manufacturing facility by 2013, eliminating more than 600 jobs...
-
Will there be more Crestor for all? I am guessing the side effects of rising blood sugar levels still may need to be addressed, even with the report to determine which issue is more profound. With the cost of the product versus the generic version, this might also add some impact as to availability...
-
The general public as a whole are lost when it comes to the complete understanding of how a clinical trial can benefit their potential treatment plans. There is enough information on the web by all means, but how do you get the information to an individual and explain both the potential benefits...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-07-2008
Filed under:
Filed under: Medically Related, Technology, drugs, healthcare, EHR, Pharma, PHR, clinical trials, Software integration, Point of Care, Personalized Clinical Trials
-
New abbreviation here to become acquainted with (PGx) which is pharmacogenics, and one more move in the direction of personalized medicine by big Pharma as the marketing of blockbuster drugs slowly evolves to a new business model with genomic data input becoming a part of the process to bring new drugs...